AOD9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; may appear as cake |
| Solubility class | Water-soluble | Often reconstituted in aqueous buffer |
| Typical storage temperature | −20 °C or below | Protect from light and moisture |
| Typical analytical method | RP-HPLC and mass spectrometry | Used for purity and identity |
| Common synonyms | AOD-9604; AOD9604; hGH fragment 176-191 | Research name and fragment description |
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
Argon (18Ar) has 26 known isotopes, from 29Ar to 54Ar, of which three are stable (36Ar, 38Ar, and 40Ar). On Earth, 40Ar makes up 99.6% of natural argon. The longest-lived radioactive isotopes are 39Ar with a half-life of 302 years, 42Ar with a half-life of 32.9 years, and 37Ar with a half-life of 35.01 days. All other isotopes have half-lives of less than two hours, and most less than one minute. Isotopes lighter than 38Ar decay to chlorine or lighter elements, while heavier ones beta decay to potassium. The naturally occurring 40K, with a half-life of 1.248×109 years, decays to stable 40Ar by electron capture (10.72%) and by positron emission (0.001%), and also to stable 40Ca via beta decay (89.28%). These properties and ratios are used to determine the age of rocks through potassium–argon dating. Despite the trapping of 40Ar in many rocks, it can be released by melting, grinding, and diffusion. Almost all argon in the Earth's atmosphere is the product of 40K decay, since 99.6% of Earth's atmospheric argon is 40Ar, whereas in the Sun and presumably in primordial star-forming clouds, argon consists of ~85% 36Ar, ~15% 38Ar and only trace 40Ar. Similarly, the ratio of the isotopes 36Ar:38Ar:40Ar in the atmospheres of the outer planets is measured to be 8400:1600:1. In the Earth's atmosphere, radioactive 39Ar (and to a lesser extent 37Ar) is made by cosmic ray activity, primarily from 40Ar.
== Extraction of calf rennet == Calf rennet is extracted from the inner mucosa of the fourth stomach chamber (the abomasum) of young, nursing calves as part of livestock butchering. These stomachs are a byproduct of veal production. Rennet extracted from older calves (grass-fed or grain-fed) contains less or no chymosin, but a high level of pepsin and can only be used for special types of milk and cheeses. As each ruminant produces a special kind of rennet to digest the milk of its own species, milk-specific rennets are available, such as kid goat rennet for goat's milk and lamb rennet for sheep's milk.
=== In animals === In dogs, sheep, horses, and cattle, the half-life is very short: only 1– 6 minutes. Complete elimination of the drug can take up to 23 minutes in sheep and up to 49 minutes in horses. In young rats the half-life is one hour. Xylazine has a large volume of distribution of Vd = 1.9 –2.5 for horses, cattle, sheep, and dogs. Though the peak plasma concentrations are reached in 12 –14 minutes in all species, the bioavailability varies between species. The half-life depends on the age of the animal, as age is related to prolonged duration of anesthesia and recovery time. Toxicity occurs with repeated administration, given that the metabolic clearance of the drug is usually calculated as 7– 9 times the half-life, which is 4 to 5 days for the clearance of xylazine.
Sources: en.wikipedia.org
Some infections, for example, those from the common cold and influenza, do not confer any long-lasting immunity. Such infections may give temporary resistance but do not give long-term immunity upon recovery from infection, and individuals become susceptible again.
The Waitangi Tribunal releases an interim report urging the New Zealand Crown to halt work on the proposed Regulatory Standards Bill and to engage in "meaningful consultation" with Māori. Deputy Prime Minister Winston Peters, Regional Development Minister Shane Jones, Labour Party MP Ingrid Leary attend a reopening ceremony at Hillside Engineering. Pro-Palestine, transgender rights, pay equity and climate change protesters picket the event. 20 May: Foreign Minister Winston Peters joins 22 other foreign ministers and the European Union in calling on Israel to allow a full resumption of aid to the Gaza Strip. Two groups of protesters gather outside the New Zealand Parliament to call for the NZ Government to lower the bowel cancer screening age and oppose the suspension of three Te Pāti Māori MPs. The New Zealand Parliament votes to postpone a debate on the Privileges Committee's decision to suspend three Te Pāti Māori MPs until 5 June, allowing them to participate in an upcoming debate around the 2025 New Zealand budget. 22 May: Finance Minister Nicola Willis releases the 2025 New Zealand budget. The Wellington City Council votes to preserve the historic Begonia House and Khandallah Pool, while making cutbacks in transport infrastructure and renovations to Wellington Zoo. The Council also introduces parking fees for motorcycles in the Wellington CBD. 23 May – The New Zealand Geographic Board and Land Information Minister Chris Penk decline a proposal by the Kororāreka Marae Society to rename Russell to its Māori language name "Kororāreka".
== U == Ultradian rhythm A recurrent biological cycle that occurs more than once in 24 hours, such as stages of sleep. In neuroscience, it refers to shorter rhythms regulating hormonal release, arousal, or sleep cycles. Unconditioned response In classical conditioning, an automatic, reflexive response to an unconditioned stimulus (e.g., salivation to food). Studied in behavioral neuroscience. Unconsciousness A state in which an individual is not aware of themselves or their surroundings. Can result from head injury, anesthesia, or metabolic dysfunction. Uncus A structure on the medial surface of the temporal lobe, part of the parahippocampal gyrus. It is involved in olfaction and is adjacent to the amygdala. Undershoot The hyperpolarizing phase following an action potential where membrane potential temporarily becomes more negative than resting potential. Unilateral neglect A neuropsychological condition following damage (typically to the right parietal lobe) in which patients ignore stimuli on one side of space. Unipolar depression A mood disorder characterized by persistent low mood, lack of energy, and anhedonia, without manic episodes. Associated with altered activity in the prefrontal cortex and limbic structures. Unipolar neuron A type of neuron with a single process extending from the cell body. Common in invertebrates and found in human sensory neurons. Upper motor neuron A neuron originating in the cerebral cortex or brainstem that transmits motor signals to lower motor neurons. Damage leads to spasticity, hyperreflexia, and weakness.
Sources: en.wikipedia.org
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.
Reversed-phase HPLC and mass spectrometry are standard checks. They confirm peptide purity and molecular mass, but they do not by themselves demonstrate biological activity.
Synthesis, purification, and handling conditions can differ, leading to variations in purity and salt content. Certificates of analysis help, but independent testing is often needed for verification.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.